Abivax (NASDAQ:ABVX) Stock Rating Upgraded by Jefferies Financial Group

Abivax (NASDAQ:ABVX) was upgraded by investment analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research note issued on Tuesday,Benzinga reports. The firm currently has a $158.00 price target on the stock, up from their previous price target of $108.00. Jefferies Financial Group’s target price would indicate a potential upside of 18.53% from the company’s previous close.

Several other analysts also recently weighed in on the company. Leerink Partners lifted their target price on Abivax from $140.00 to $148.00 and gave the company an “outperform” rating in a research note on Tuesday. Wolfe Research set a $136.00 target price on shares of Abivax in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Citigroup restated an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Fourteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $144.46.

Abivax Stock Up 38.6%

Shares of NASDAQ:ABVX traded up $37.15 during midday trading on Tuesday, reaching $133.30. The company’s stock had a trading volume of 8,520,534 shares, compared to its average volume of 1,554,016. The firm has a market cap of $10.63 billion, a price-to-earnings ratio of -25.58 and a beta of 0.69. The business has a 50 day moving average price of $110.78 and a 200 day moving average price of $117.38. Abivax has a 1 year low of $7.41 and a 1 year high of $148.83.

Abivax (NASDAQ:ABVX) last issued its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. Sell-side analysts anticipate that Abivax will post -3.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GHP Investment Advisors Inc. grew its stake in shares of Abivax by 155.6% in the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after purchasing an additional 140 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after buying an additional 369 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after buying an additional 344 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in Abivax during the 4th quarter worth about $61,000. Finally, WPG Advisers LLC grew its holdings in Abivax by 125.9% during the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after acquiring an additional 253 shares during the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax News Summary

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Abivax reported positive ABTECT Maintenance Part 2 results for obefazimod, showing meaningful clinical benefit in refractory ulcerative colitis patients and strengthening the Phase 3 maintenance safety database. Article: Abivax Reports Positive ABTECT Maintenance Part 2 Results…
• Positive Sentiment: Updated clinical data eased safety concerns by showing malignancy rates were consistent with expected background levels, reducing a major overhang on the stock. Article: Abivax shares jump as updated trial data eases safety concerns
• Positive Sentiment: Analysts turned more constructive, with Leerink Partners raising its price target to $148 and keeping an outperform rating, signaling increased confidence in the pipeline and potential upside. Article: Leerink price target raise
• Neutral Sentiment: Wedbush also raised its price target, but kept a neutral rating, reflecting some lingering caution despite the improved data. Article: Wedbush price target raise

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.